

#9

VPI 99-06 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Not Yet Known
Group Art Unit: Not Yet Known
Applicants: Salituro et al.,
Serial No.: 10/008,277
Filing Date: December 3, 2001
For: INHIBITORS OF c-JUN N-TERMINAL (JNK)
KINASES

Cambridge, Massachusetts
May 17, 2002

Hon. Commissioner
For Patents
Washington, D.C. 20231

VERIFIED STATEMENT UNDER 37 C.F.R. §1.821(f)

Sir:

I declare that the information recorded in computer readable form attached hereto is identical to the written sequence listing in the application filed December 3, 2001.

Respectfully submitted,

Andrea L.C. Robidoux
(Reg. No. 47,902)
Agent for Applicants
Vertex Pharmaceuticals Inc.,
130 Waverly Street
Cambridge, MA 02193-4242
(617) 444-6731
(617) 444-6438 (fax)

Express Mail Label No.: EU206590371
 Date of Deposit: May 17, 2002

US

Attorney Docket No. VPI/99-06 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Francesco Salituro et al.,
 ASSIGNEE: Vertex Pharmaceuticals Incorporated
 SERIAL NUMBER: 10/008,277 EXAMINER: Not Yet Assigned
 FILING DATE: December 3, 2002 ART UNIT: Not Yet Assigned
 FOR: INHIBITORS OF c-JUN N-TERMINAL (JNK) KINASES

May 17, 2002
 Cambridge, Massachusetts

Box SEQUENCE
 Assistant Commissioner for Patents
 Washington, D.C. 20231

**SUBMISSION OF PAPER COPY AND/OR COMPUTER-READABLE
 COPY OF SEQUENCE LISTING FOR INVENTION CONTAINING
 NUCLEOTIDE AND/OR AMINO ACID SEQUENCE**

1. ☒ This paper is in response to the Patent Office letter dated May 8, 2002.
☒ A copy of the Patent Office letter is enclosed.

Note: If these papers are filed before the Patent Office letter is mailed, the adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of the invention, the filing date on the Express Mail Label, the USSN from the return postcard or the attorney's docket number must be added.

☒ This paper is in compliance with the requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures.
2. Submitted herewith are:
 - ☐ A Preliminary Amendment directing entry of the Sequence Listing into the specification;
 - ☒ a paper copy of the Sequence Listing for the above-identified patent application with each sequence assigned a separate identifier; and
 - ☒ a copy of the Sequence Listing in computer-readable form for the above-identified patent application.

APPLICANTS:
U.S.S.N.:


3. **Statement:**

I hereby state that: *(complete applicable items – A, B and/or C)*

- A. ☒ The content of the paper and computer-readable copies of the Sequence Listing submitted herewith are the same.
- B. ☐ The content of the computer-readable copy of the Sequence Listing submitted herewith is the same as the Sequence Listing appearing at the end of the originally-filed specification.
- C. ☒ This submission includes no new matter.

Applicants believe that no fee is required for the filing of the present submission. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment, to Deposit Account No. 50-0725, Ref. No. VPI/99-06 CON.

Respectfully submitted,



Andrea L.C. Robidoux

Reg. No. 47,902

Agent for Applicants

c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139-4242
Tel: (617) 444-6731
Fax: (617) 444-6483

Dated: May 17, 2002

TRADOCS:1253257.1(QV0P01!.DOC)